宫瘤消胶囊联合地诺孕素治疗难治/复发性子宫内膜异位症的疗效和机制OA
Clinical effect and mechanism of Gongliuxiao capsule combined with dienogest in treating refractory/recurrent endometriosis
目的 探讨宫瘤消胶囊联合地诺孕素(DNG)治疗难治/复发性子宫内膜异位症(EMT)的临床效果和机制.方法 回顾性分析青岛市中医医院2022年1月-2025年1月收治的94例难治/复发性EMT患者的临床资料,根据治疗方法不同分为单药组(予以DNG单药治疗)和联合组(予以宫瘤消胶囊联合DNG治疗),各47例.比较两组患者的临床疗效和治疗前及治疗6个月后的症状体征[视觉模拟疼痛评分法(VAS)和月经失血图(PBAC)评分]、血管内皮功能指标[血清转化生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)、基质金属蛋白酶2(MMP-2)、MMP-9、碱性成纤维细胞生长因子(bFGF)]、血清病理相关因子[糖类抗原125(CA125)、CA199、抗子宫内膜抗体(EMAb)]和Th1/Th2漂移指标[干扰素-γ(IFN-γ)、白细胞介素4(IL-4)]水平.结果 治疗后,两组患者的VAS和PBAC评分,血清TGF-β1、VEGF、MMP-2、MMP-9、bFGF、CA125、CA199和EMAb及IL-4水平均显著低于治疗前,IFN-γ水平均显著高于治疗前(P<0.05),且联合组患者升高/降低的幅度均显著大于单药组(P<0.05).联合组患者的总有效率显著高于单药组(93.62%vs.76.60%,P<0.05).结论 宫瘤消胶囊联合DNG治疗难治/复发性EMT的疗效肯定,可有效改善患者的痛经程度及月经量异常;其机制可能与改善血管内皮功能、抑制肿瘤病理因子表达、纠正Th1/Th2漂移有关.
OBJECTIVE To investigate the clinical efficacy and mechanism of Gongliuxiao capsule combined with dienogest(DNG)in the treatment of refractory/recurrent endometriosis(EMT).METHODS A retrospective analysis was conducted on the clinical data of 94 patients with refractory/recurrent EMT admitted to Qingdao TCM Hospital from January 2022 to January 2025.According to different treatment methods,they were divided into a monotherapy group(47 cases,receiving DNG monotherapy)and a combination group(47 cases,receiving Gongliuxiao capsule combined with DNG).The clinical efficacy,symptom and sign scores[Visual Analog Scale(VAS)and Pictorial Blood Loss Assessment Chart(PBAC)scores],vascular endothelial function indicators[serum transforming growth factor-β1(TGF-β1),vascular endothelial growth factor(VEGF),matrix metalloproteinase-2(MMP-2),MMP-9,basic fibroblast growth factor(bFGF)],serum pathological factors[carbohydrate antigen 125(CA125),CA199,anti-endometrial antibody(EMAb)],and Th1/Th2 drift indicators[interferon-γ(IFN-γ),interleukin-4(IL-4)]were compared between the two groups before and after 6 months of treatment.RESULTS After treatment,the VAS and PBAC scores,serum levels of TGF-β1,VEGF,MMP-2,MMP-9,bFGF,CA125,CA199,EMAb,and IL-4 in both groups were significantly lower than those before treatment,while IFN-γ levels were significantly higher than those before treatment(P<0.05).Moreover,the magnitude of increase or decrease in the combination group was significantly greater than that in the monotherapy group(P<0.05).The total effective rate in the combination group was significantly higher than that in the monotherapy group(93.62%vs.76.60%,P<0.05).CONCLUSIONS The combination of Gongliuxiao capsule and DNG is effective in treating refractory/recurrent EMT,and can effectively improve the degree of dysmenorrhea and abnormal menstrual volume in patients.The mechanism may be related to improving vascular endothelial function,inhibiting the expression of tumor pathological factors,and correcting Th1/Th2 drift.
袁汇;毛亚林;徐向前;陈雨龙;孔守芳
青岛市中医医院/青岛市海慈医院/青岛大学附属青岛市海慈医院妇二科,山东 青岛 266033青岛市市北区卫生健康事业发展中心计划生育协会办公室,山东 青岛 266034青岛市中医医院/青岛市海慈医院/青岛大学附属青岛市海慈医院泌尿外科,山东 青岛 266033青岛大学附属医院妇科,山东 青岛 266003青岛市中医医院/青岛市海慈医院/青岛大学附属青岛市海慈医院妇二科,山东 青岛 266033
医药卫生
子宫内膜异位症难治/复发性宫瘤消胶囊地诺孕素联合治疗血管内皮功能Th1/Th2漂移
endometriosisrefractory/recurrentGongliuxiao capsuledienogestcombination therapyvascular endothelial functionTh1/Th2 drift
《中国药房》 2026 (11)
1468-1472,5
山东省医药卫生科技项目(No.202405010785)
评论